OncoMatch/Clinical Trials/NCT04590664
Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
Is NCT04590664 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Verteporfin for glioblastoma.
Treatment: Verteporfin — This phase I/II trial studies the side effects and best dose of Visudyne (liposomal verteporfin) and to see how well it works in treating patients with high grade EGFR-mutated glioblastoma that has come back (recurrent). Visudyne is FDA approved in combination with light to treat eye diseases. In this study we use Visudyne by itself like chemotherapy to kill tumor cells which may be sensitive to verteporfin.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: EGFR mutant or amplified
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: radiation therapy — brain
All participants on this study must have had prior radiation to the brain. Radiation must have been completed 90 days prior to first study treatment
Must have received: chemotherapy (temozolomide) — first line
should have received standard first line therapy including radiation and temozolomide
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Emory University Hospital/Winship Cancer Institute · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify